Journal
HELIYON
Volume 4, Issue 12, Pages -Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.heliyon.2018.e01021
Keywords
Cancer research; Pharmaceutical science; Molecular biology
Categories
Funding
- JSPS KAKENHI [17H04282, 17K19698, 16K15615, 15H05791]
- Extramural Collaborative Research Grant of Cancer Research Institute, Kanazawa University
- Grants-in-Aid for Scientific Research [16K15615] Funding Source: KAKEN
Ask authors/readers for more resources
Many anticancer drugs have serious adverse effects; therefore, it is necessary to target features specific to cancer cells to minimize the effects on healthy cells. Methylenetetrahydrofolate dehydrogenase 2 (MTHFD2) was reported to be specifically enhanced in cancer. We confirmed the validity of MTHFD2 as a drug discovery target using clinical data. In addition, we performed in silico screening to design an anticancer drug specifically targeting MTHFD2. Analysis of the clinical data indicated that MTHFD2 was enhanced in most cancers compared with normal tissues, and affected the prognosis in cancer patients. Candidate compounds for MTHFD2 inhibitors were identified using in silico drug discovery techniques, and the important interactions for MTHFD2 binding were determined. In addition, these candidate compounds decreased levels of MTHFD2 metabolites in cancer cells. The findings of the present study may help to develop anticancer drugs targeting MTHFD2, with a view to minimizing the adverse effects of anticancer drugs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available